Outset Medical, Inc. Provides Revenue Guidance Fourth Quarter and Full Year Ended December 31, 2022 and for the Year 2023
January 09, 2023 at 08:30 am
Share
Outset Medical, Inc. provided unaudited preliminary net sales results fourth quarter and full year ended December 31, 2022. For the quarter, the company expects revenue approximately $31.5 million, a 13% increase compared to $27.8 million in the third quarter of 2022.
For the year, the company expects revenue of $122.2 million, a decrease of approximately 2% on a reported basis and essentially flat on a constant currency basis over prior year.
For the year 2023, the company expects revenue to be between $140 million to $150 million, growing approximately 22% to 30% over expected revenue for 2022.
Outset Medical, Inc. is a medical technology company. The Company offers Tablo Hemodialysis System (Tablo), which is a single enterprise solution for hemodialysis, comprised of a compact console with integrated water purification, on-demand dialysate production and advanced software and connectivity capabilities. The Company designed Tablo from the ground up to be a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by virtually anyone. The Tablo system comprises components, which include Tablo Console, Tablo Cartridge and Tablo Data Ecosystem. Tablo Console is a compact, mobile and versatile machine consisting of an integrated water purification, on-demand dialysate production system and touchscreen interface with 3D animations. It also offers various key platforms, such as TabloHub, a customer-facing portal; MyTablo, a patient-facing portal, and TabloDash, an internal data analytics platform.
OUTSET MEDICAL, INC. 
